Emerging oral drugs for erectile dysfunction

Bibliography

• JARDIN A, WAGNER G, KHOURI S et al: Recommendations of the 1st International Consultation on Erectile Dysfunction. In: Erectile Dysfunction. Jardin A, Wagner G, Khouri S, Giuliano F, Padma Nathan H, Rosen R (Eds). Health Publication Ltd, Plymouth, UK (2000):709–726.
   Google Scholar
• ARVER S, DOBS AS, MEIKLE AW, ALLEN RP, SANDERS SW, MAZER NA: Improvement of sexual function in testosterone deficient men treated for 1 year with a permeation enhanced testosterone transdermal system. ./. Urol. (1996) 155(5):1604–1608.
   Web of Science ®Google Scholar
• SCHULTEISS D, HILTL DM, MESCHI MR et al: Pilot study of the transdermal application of testosterone gel to the penile skin for the treatment of hypogonadotropic men with erectile dysfunction. World J. Um]. (2000) 18:431–435.
   PubMed Web of Science ®Google Scholar
• MEULEMAN E, BRODERICK G, MENG TAN H et al: Clinical evaluation and the doctor-patient dialogue. In: Erectile Dysfunction. Jardin A, Wagner G, Khouri S, Giuliano F, Padma Nathan H, Rosen R (Eds). Health Publication Ltd, Plymouth, UK (2000):115–138.
   Google Scholar
• NIH: Consensus Development Panel on Impotence. JAMA (1993) 270:83–90.
   PubMed Web of Science ®Google Scholar
• MONTORSI F, GUAZZONI G, RIGATTI P et al. Pharmacological management of erectile dysfunction. Drugs (1995) 50:465–479.
   PubMed Web of Science ®Google Scholar
• HEATON JP: Central neuropharmacological agents and mechanisms in erectile dysfunction: the role of dopamine. Neuro. Bio. Rev (2000) 24: 507–516.
   Google Scholar
• ANDERSSON KE: Pharmacology of erectile function and dysfunction. Urol. Clin. North Ain. (2001) 28:233–247.
   PubMed Web of Science ®Google Scholar
• ••This paper is an excellent review ofpathophysiology and molecular targets Implicated in erectile function and dysfunction.
   Google Scholar
• STIEF CG: Is there a common pathophysiology of erectile dysfunction and how does this relate to new pharmacotherapies? Int. J. Impact. Res. (2002) 14\(Suppl. 1):S11–516.
   Google Scholar
• HOLMQUIST F, STIEF CG, JONAS U et al.: Effects of nitric oxide synthase inhibitor NG-nitro-L-arginine on the erectile response to cavernous nerve stimulation in the rabbit. Acta Physic] Scand. (1991) 143:299–304.
   PubMedGoogle Scholar
• TRIGO-ROCHA F, ARONSON WJ, HOHENFELLNER M et al: Nitric oxide and cGMP: mediators of pelvic nerve-stimulated erection in dogs. Ain. Physiol (1993) 264:H419–H422.
   PubMed Web of Science ®Google Scholar
• AZADZOI KM, KIM N, BROWN ML et al.: Endothelium derived nitric oxide and cyclooxygenase products modulate corpus cavernosum smooth muscle tone. ./. Urol. (1992) 147:220–225.
   Web of Science ®Google Scholar
• KUTHE A, WIEDENROTH A, MAGERT HJ et al.: Expression of different phosphodiesterase genes in human cavernous smooth muscle. J. Um]. (2001) 165: 280–283.
   Web of Science ®Google Scholar
• ••This basic science research elucidatesdistribution of PDE genes in corpus cavernosum, indicating a role of these enzymes in penile erection regulation.
   Google Scholar
• KUTHE A, MAGERT H, UCKERT S et al.: Gene expression of the phosphodiesterases 3A and 5A in human corpus cavernosum penis. Eur. Uri)] (2000) 38:108–114.
   PubMed Web of Science ®Google Scholar
• OCKERT S, KUTHE A, STIEF CG et al.: Phosphodiesterase isoenzymes as pharmacological targets in the treatment of male erectile dysfunction. World J. Um]. (2001) 19: 14–22.
   PubMed Web of Science ®Google Scholar
• LIN CS, LAU A, TU R et al.: Expression of three isoforms of cGMP binding cGMP-specific phosphodiesterase (PDE5) in human penile cavernosum. Biochem. Biophys. Res. Commun. (2000) 268:628–635.
   PubMed Web of Science ®Google Scholar
• ANDERSSON KE, HEDLUND P: New directions for erectile dysfunction therapies. Int. Impot. Res. (2002) 14\(Suppl. 1):582–592.
   Google Scholar
• GOLDSTEIN I, LUE TF, PADMA-NATHAN H et al: Oral sildenafil in the treatment of erectile dysfunction. N Engl. I Med. (1998) 338:1397–1404.
   PubMed Web of Science ®Google Scholar
• ROSENBERG KP: Sildenafil citrate for SSRI-induced sexual side effects. Am. J. Psychiatry (1999) 156:157.
   PubMed Web of Science ®Google Scholar
• Pfizer, NY, USA, FDA submission: Viagra labelling information. (1997).
   Google Scholar
• MUIRHEAD GJ, ALLEN MJ, JAMES GC et al: Pharmacokinetics of sildenafil (Viagra), a selective cGMP PDE5 inhibitor, after single oral doses in fasted and fed healthy volunteers. BE J. Clia Pharmacol (1996) 42:268.
   Google Scholar
• WALKER DK, ACKLAND MJ, JAMES GC et al.: Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. Xenobiotica (1999) 29:297–310.
   PubMed Web of Science ®Google Scholar
• WARRINGTON JS, SHADER RI, VON MOLTKE LL et al: In vitro biotrasformation of sildenafil (Viagra): identification of human cytochromes and potential drug interactions. Drug Metab. Dispos. (2000) 28:392–397.
   PubMed Web of Science ®Google Scholar
• MONTORSI F, MCDERMOTT T, MORGAN R et al.: Efficacy and safety of fixed-dose oral sildenafil in the treatment of erectile dysfunction of various etiologies. Urology (1999) 53:1011–1018.
   PubMed Web of Science ®Google Scholar
• KRENZELOK EP: Sildenafil: clinical toxicology profile. J. Toxicol Chit Toxicol (2000) 38:645–651.
   PubMed Web of Science ®Google Scholar
• ASHTON AK, BENNET RG: Sildenafil treatment of serotonin reuptake inhibitor-induced sexual dysfunction. Clin. Psychiatry (1999) 60:194–195.
   PubMed Web of Science ®Google Scholar
• NURNBERG HG, LAURIELLO J, HENSLEY PL et al.: Sildenafil for iatrogenic serotoninergic antidepressant medication-induced sexual dysfunction in 4 patients.' Chit Psychiatry (1999) 60:33–35.
   PubMed Web of Science ®Google Scholar
• ROSENBERG KP: Sildenafil citrate for SSRI-induced sexual side effects. Am. J. Psychiatry (1999) 156:157.
   PubMed Web of Science ®Google Scholar
• NANDWANI R, GOURLAY Y: Possible interaction between sildenafil and HIV combination therapy. Lancet (1999) 353:840.
   PubMed Web of Science ®Google Scholar
• MUIRHEAD GJ, WULFF MB, FIELDING A et al.: Pharmacokinetic interaction between sildenafil and saquinavidritonavir. BL J. Clin. Pharmacol (2000) 50:99–107.
   Web of Science ®Google Scholar
• MILLIGAN PA, MARSHALL SF, KARLSSON MO: A population pharmacokinetic analysis of sildenafil citrate in patients with erectile dysfunction. BE J. Clin. Pharmacol (2002) 53:S45–S52.
   Google Scholar
• BOOLELL M, ALLEN MJ, BALLARD SA et al.: Sildenafil: an orally active Type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int. J. Impot. Res. (1996) 8:47–52.
   PubMedGoogle Scholar
• GUAY AT, PEREZ JB, JACOBSON J et al: Efficacy and safety of sildenafil citrate for treatment of erectile dysfunction in a population with associated organic risk factors. I. Andra (2001) 22:793–797.
   PubMed Web of Science ®Google Scholar
• CONTI CR, PEPINE CJ, SWEENEY M: Efficacy and safety of sildenafil citrate in the treatment of erectile dysfunction in patients with ischemic heart disease. Am. J. Cardiol (1999) 83:C29–C34.
   Google Scholar
• MORALES A, GINGELL C, COLLINS M et al.: Clinical safety of sildenafil citrate (Viagra) in the treatment of erectile dysfunction. Int. I. Livia. Re.c. (1998) 10:69–73.
   Web of Science ®Google Scholar
• WALLIS RM, CORBIN JD, FRANCIS SH et al: Tissue distribution of phosphodiesterase families and effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. Am. J. Cardiol (1999) 83(Suppl. 5A):3C–12C.
   Google Scholar
• LINA S: On behalf of the Mexico and Brazil Sildenafil Study Group: efficacy and safety of oral Viagra® (sildenafil citrate) for the treatment of erectile dysfunction in Latin America. Congreso del la Con federacion Americana de Urologia, Bueno Aires, Argentina (2000).
   Google Scholar
• LEVINSON I, KHALAF I, MAHMOUD KZ: Efficacy of Viagra® (sildenafil citrate) in men with erectile dysfunction in two African Countries. 98th Annual Meeting of New York Section of the American Urological Association, Cape Town, South Africa (2000).
   Google Scholar
• TAN HM, CHANG MOH CL, MENDOZA JB et al: For the ASSESS-1 Study Group. Asian sildenafil efficacy and safety study (ASSESS-1): a double-blind, placebo-controlled, flexible-dose study of oral sildenafil in Malaysian, Singaporean, and Filipino men with erectile dysfunction. Urology (2000) 56: 635–640.
   Google Scholar
• YINGLU G: Efficacy and safety of oral sildenafil in the treatment of erectile dysfunction in Chinese patients. 5th Asian Congress in Urology Beijing, China (2000).
   Google Scholar
• MCMAHON CG, SAMALI R, JOHNSON H: Efficacy, safety and patient acceptance of sildenafil citrate as treatment for erectile dysfunction. J. Urol. (2000) 164:1192–1196.
   PubMed Web of Science ®Google Scholar
• SAD OVSKY R, MILLER T, MOSKOWITZ M et al: Three-year update of sildenafil citrate (Viagra®) efficacy and safety. IntlPract. (2001)55:115–128.
   Google Scholar
• ROSEN RC, RILEY A, WAGNER G et al:The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology (1997) 49:822-830. This paper represents the first published report of the IIEF, a widely used validated-self assessment scale that investigates, not only ED but all the areas of male sexual life.
   Google Scholar
• BOULTON AJM, SELAM JL, SWEENEY M et al: Sildenafil citrate for the treatment of erectile dysfunction in men wiith Type II diabetes mellitus. Diabetologia (2001) 44:1296–1301.
   PubMed Web of Science ®Google Scholar
• CARSON CC, BURNETT AL, LEVINE LA et al: The efficacy of sildenafil citrate (Viagra) in clinical populations: an update. Urology (2002) 60(2, Suppl. 2):12–27.
   PubMed Web of Science ®Google Scholar
• GIULIANO F, MONTORSI F, MIRONE V et al: Switching from intracavernous prostaglandin El injections to oral sildenafil citrate in patients with erectile dysfunction: results of a multicenter European study. I. Urol. (2000) 164:708–711.
   PubMed Web of Science ®Google Scholar
• HATZICHRISTOU DG, APOSTOLIDIS A, TZORTZIS V et al: Sildenafil versus intracavernous injection therapy: efficacy and preference in patients on intracavernous injection for more than 1 year. J. Urol. (2000) 164:1197–1200.
   PubMed Web of Science ®Google Scholar
• SAIRAM K, KULINSKAYA E, HANBURY D et al: Oral sildenafil (ViagraTM) in male erectile dysfunction: use, efficacy and safety profile in an unselected cohort presenting to a British district general hospital. BMC Urol. (2002) 2:4.
   PubMedGoogle Scholar
• MOORE RA, EDWARDS JE, MCQUAY HJ: Sildenafil (ViagraTM) for male erectile dysfunction: a meta-analysis of clinical trial reports. BMC Urol. (2002) 2:6.
   PubMedGoogle Scholar
• FINK HA, MACDONALD R, RUTKS IR et al: Sildenafil for male erectile dysfunction. A systematic review and meta-analysis. Arch. Intern. Med. (2002) 162:1349–1360.
   PubMed Web of Science ®Google Scholar
• FAGELMAN E, FAGELMAN A, SHABSIGH R: Efficacy, safety, and use of sildenafil in urologic practice. Urology (2001) 57:1141–1144.
   PubMed Web of Science ®Google Scholar
• LEWIS R, BENNET CJ, BORKON WD et al: Patient and partner satisfaction with Viagra (sildenafil citrate) treatment as determined by the Erectile Dysfunction Inventory of Treatment Satisfaction Questionnaire. Urology (2001) 57:960–965.
   PubMed Web of Science ®Google Scholar
• ALTHOF SE, CORTY EW, LEVINE SB: Edits: development of questionnaires for evaluating satisfaction with treatments for erectile dysfunction. Urology (1999) 53:793–799.
   PubMed Web of Science ®Google Scholar
• PATTERSON B, BEDDING A, JEWELL H et al.: Dose-normalized pharmacokinetics of single dose-tadalafil (IC351) in healthy volunteers. Int. J. Impot. Res. (2001) 13\(Suppl. 5):562 (Abstract 14).
   Google Scholar
• ANGULO J, GADAU M, FERNANDEZ A et al.: IC351 enhances NO-mediated relaxation of human arterial and trabecular penile smooth muscle. Eur. Urol. (2001) 39:106 (Abstract 415).
   PubMed Web of Science ®Google Scholar
• EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR): Summary of product characteristics: cialis. First published June 12, 2002.
   Google Scholar
• PADMA-NATHAN H, ROSEN RC, SHABSIGH R et al: Cialis (IC351) provides prompt response and extended period of responsiveness in the treatment of men with erectile dysfunction (ED). I Urol. (2001) 165(Suppl.):A923.
   Google Scholar
• PADMA-NATHAN H, MCMURRAY JG, PULLMAN WE et al: On demand IC351 (Cialis) enhances erectile function in patients with erectile dysfunction. Lit. J. Impot. Res. (2001) 13:2–9.
   PubMed Web of Science ®Google Scholar
• PORST H Daily IC351 treatment of ED. Int. J. Lima Res. (2000) 12(Suppl. 3):576, A-B13.
   Google Scholar
• SAENZ DE TEJADA I, EMMICK J, ANGLIN G et al.: The effect of as-needed tadalafil (IC351) treatment of erectile dysfunction in men with diabetes. Int. Impot. Res. (2001) 13\(Suppl. 4):A128.
   Google Scholar
• ROSEN RC, CAPPELLERI JC, GENDRANO N 3rd: The International Index of Erectile Function (IIEF): a state-of-the-science review. Int. J. Impot. Res. (2002) 14:226–244.
   PubMed Web of Science ®Google Scholar
• MONTORSI F, MCCULLOUGH A, BROCK GB et al.: Tadalafil in the treatment of erectile dysfunction following bilateral nerve-sparing radical retropubic prostatectomy: a randomized, double-blind, placebo-controlled trial../. Urol. (2004) (Submitted).
   Google Scholar
• •This research underlines the efficacy and safety of tadalafil in a difficult to treat population represented by patients affected by localised prostate cancer who underwent nerve-sparing radical prostatectomy.
   Google Scholar
• PATTERSON B, BEDDING A, JEWELL H et al.: The effect of intrinsic and extrinsic factors on the pharmacokinetic properties of tadalafil (IC351). Int. J. Impot. Res. (2001) 13\(Suppl. 4):A120.
   Google Scholar
• PORST H: IC351 (tadalafil, Clans): updateon clinical experience. Int. J. Impot. Res. (2002) 14\(Suppl. 1):557–564.
   Google Scholar
• KLONER RA, MITCHELL M, EMMICK JT: Cardiovascular effects of tadalafil in patients on common antihypertensive therapy. Am. J. Cardiology (2003) 92\(Suppl. 1):47–57.
   PubMed Web of Science ®Google Scholar
• •As shown by this paper, tadalafil is provided with an excellent profile in terms of safety which was also found in patients affected by hypertension who were treated with oral therapy.
   Google Scholar
• KLONER RA, HUTTER AM, EMMICK JT et al.: Time course of the interaction between tadalafil and nitrates. J. Am. Coll. Cardiol (2003) 42:1855–1860.
   PubMed Web of Science ®Google Scholar
• HELLSTROM WJG, OVERSTREET JW, YU A et al.: Tadalafil has no detrimental effect on human spermatogenesis or reproductive hormones. J. Urol. (2003) 170:887–891.
   PubMed Web of Science ®Google Scholar
• •This research has clearly underlined the safety profile of tadalafil, in terms of spermatogenesis, as its potential Interaction with PDE5–11, found in the testis, had previously raised questions about this issue.
   Google Scholar
• STARK S, SACHSE R, LIEDL T et al.: Vardenafil increases penile rigidity and tumescence in men with erectile dysfunction after a single oral dose. Eur. Urol. (2001) 40:181–190.
   PubMed Web of Science ®Google Scholar
• KLOTZ T, SACHSE R, HEIDRICH A et al: Vardenafil increases penile rigidity and tumescence in erectile dysfunction patients: a RigiScan and pharmacokinetic study. World J. Urol. (2001) 19:32–39.
   PubMed Web of Science ®Google Scholar
• PORST H, ROSEN R, PADMA-NATHAN H et al.: The efficacy and tolerability of vardenafil, a new, oral selective PDE-5 inhibitor, in patients with erectile dysfunction: first at-home clinical trial. Int. J. Impot. Res. (2001) 13:192–199.
   PubMed Web of Science ®Google Scholar
• GOLDSTEIN I, YOUNG JM, FISCHER J et al: Vardenafil, a new phosphodiesterase Type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study. Diabetes Care (2003) 26:777–783.
   PubMed Web of Science ®Google Scholar
• BROCK G, NEHRA A, LIPSHULTZ LI et al.: Safety and efficacy of vardenafil for the treatment of men with erectile dysfunction after radical prostatectomy. Urol. (2003) 170:1278–1283.
   Web of Science ®Google Scholar
• HELLSTROM WJ, GITTELMAN M, KARLIN G et al.: Sustained efficacy and tolerability of vardenafil, a highly potent selective phosphodiesterase Type 5 inhibitor, in men with erectile dysfunction: results of a randomized, double-blind, 26-week placebo-controlled pivotal trial. Urology (2003) 61(4, Suppl. 1):8–14.
   PubMed Web of Science ®Google Scholar
• •This research underlines the efficacy and safety of vardenafil, in a difficult to treat population represented by patients affected by localised prostate cancer who underwent radical prostatectomy.
   Google Scholar
• THADANI U, SMITH W, NASH S et al: The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease. J. Am. Coll Cardiol (2002) 4(40):2006–2012.
   Web of Science ®Google Scholar
• PRYOR JP Vardenafil: update on clinical experience. Int. J. Impot. Res. (2002) 14(Suppl. 1): S65–S69.
   PubMed Web of Science ®Google Scholar
• MELIS MR, ARGIOLAS A: Central oxytocinergic neurotransmission: a drug target for the therapy of psychogenic erectile dysfunction. Curr. Drug Targets (2003) 4:55–66.
   PubMed Web of Science ®Google Scholar
• ARGIOLAS A, MELIS MR: Neuromodulation of penile erection: an overview of the role of neurotransmitters and neuropeptides. Progr. Neurobiol (1995) 47:235–255.
   PubMed Web of Science ®Google Scholar
• MIRONE VG, STIEF CG: Efficacy of apomorphine SL in erectile dysfunction. EILI Int. (2001) 88\(Suppl. 3):25–29.
   Google Scholar
• DULA E, BUKOFZER S, PERDOK R et al.: Double-blind, crossover comparison of 3 mg apomorphine SL with placebo and with 4 mg apomorphine SL in male erectile dysfunction. Eur. Urol. (2001) 39:558–564.
   PubMed Web of Science ®Google Scholar
• HEATON JP, DEAN J, SLEEP DJ: Sequential administration enhances the effect of apomorphine in men with erectile dysfunction. Int. I Impot. Res. (2002) 14:61–64.
   PubMed Web of Science ®Google Scholar
• MONTORSI F: Tolerability and safety of apomorphine SL (Ixense (TM)). hit. Impot. Res. (2003) 15\(Suppl. 2):S7–S9.
   PubMed Web of Science ®Google Scholar
• BUVAT J, MONTORSI F: Safety and tolerability of apomorphine SL in patients with erectile dysfunction. BJUInt. (2001) 88\(Suppl. 3):30–35.
   PubMed Web of Science ®Google Scholar
• PERIMENIS P, GYFTOPOULOS K, GIANNITSAS K et al.: A comparative, crossover study of the efficacy and safety of sildenafil and apomorphine in men with evidence of arteriogenic erectile dysfunction. Int. I Impot. Res. (2004) 16:2–7.
   PubMed Web of Science ®Google Scholar